Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
656 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Diffuse Large B-Cell Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 11 Global Markets Direct Report Coverage 11 Diffuse Large B-Cell Lymphoma Overview 12 Therapeutics Development 13 Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 13 Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 14 Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 15 Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 22 Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Diffuse Large B-Cell Lymphoma - Products under Development by Companies 26 Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 34 Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 35 AbbVie Inc. 35 Acetylon Pharmaceuticals, Inc. 36 Affimed Therapeutics AG 37 Amgen Inc. 38 Aprogen, Inc. 39 Arrien Pharmaceuticals, LLC 40 Astellas Pharma Inc. 41 AstraZeneca Plc 42 Aurigene Discovery Technologies Limited 43 Bayer AG 44 BeiGene(Beijing) Co.,Ltd 45 BIND Therapeutics, Inc. 46 Biocon Limited 47 Bristol-Myers Squibb Company 48 Celgene Corporation 49 Cell>Point, L.L.C. 50 Cellular Biomedicine Group, Inc. 51 Constellation Pharmaceuticals, Inc. 52 CTI BioPharma Corp. 53 Curis, Inc. 54 Cyclacel Pharmaceuticals, Inc. 55 Eisai Co., Ltd. 56 EpiZyme, Inc. 57 Erytech Pharma SA 58 F. Hoffmann-La Roche Ltd. 59 Genentech, Inc. 60 Gilead Sciences, Inc. 61 GlaxoSmithKline Plc 62 Hutchison MediPharma Limited 63 Idera Pharmaceuticals, Inc. 64 ImmunoGen, Inc. 65 Immunomedics, Inc. 66 Immunovaccine, Inc. 67 Incyte Corporation 68 Inflection Biosciences Limited 69 Johnson & Johnson 70 Juno Therapeutics Inc. 71 Karus Therapeutics Limited 72 Karyopharm Therapeutics, Inc. 73 Kite Pharma, Inc. 74 Mabion SA 75 mAbxience S.A. 76 MedImmune, LLC 77 Medivation, Inc. 78 Merck & Co., Inc. 79 Millennium Pharmaceuticals, Inc. 80 Mirati Therapeutics Inc. 81 Mirna Therapeutics, Inc. 82 Molplex Ltd. 83 MorphoSys AG 84 Neumedicines Inc. 85 Nimbus Therapeutics, LLC 86 Nordic Nanovector ASA 87 Novartis AG 88 Ono Pharmaceutical Co., Ltd. 89 Onyx Pharmaceuticals, Inc. 90 Pfizer Inc. 91 Philogen S.p.A. 92 Portola Pharmaceuticals, Inc. 93 ProNAi Therapeutics, Inc. 94 RedHill Biopharma Ltd. 95 Redx Pharma Plc 96 Respiratorius AB 97 Rhizen Pharmaceuticals S.A. 98 Sandoz International GmbH 99 Seattle Genetics, Inc. 100 Selvita SA 101 Taiho Pharmaceutical Co., Ltd. 102 TG Therapeutics, Inc. 103 Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 104 Assessment by Monotherapy Products 104 Assessment by Combination Products 105 Assessment by Target 106 Assessment by Mechanism of Action 111 Assessment by Route of Administration 115 Assessment by Molecule Type 117 Drug Profiles 119 187Re-EC-G - Drug Profile 119 ABC-294640 - Drug Profile 120 acalabrutinib - Drug Profile 123 acalisib - Drug Profile 126 ACY-775 - Drug Profile 127 AFM-11 - Drug Profile 129 AFM-13 - Drug Profile 130 alisertib - Drug Profile 131 ARN-3236 - Drug Profile 135 ARN-3261 - Drug Profile 136 ASN-002 - Drug Profile 137 asparaginase - Drug Profile 138 atezolizumab - Drug Profile 140 azacitidine - Drug Profile 144 AZD-2811 - Drug Profile 148 AZD-3965 - Drug Profile 149 AZD-9150 - Drug Profile 151 bendamustine hydrochloride - Drug Profile 152 Betalutin - Drug Profile 155 BGB-3111 - Drug Profile 157 blinatumomab - Drug Profile 158 BLyS-gel - Drug Profile 161 BMS-986016 - Drug Profile 162 bortezomib - Drug Profile 163 brentuximab vedotin - Drug Profile 169 buparlisib hydrochloride - Drug Profile 176 BVX-20 - Drug Profile 180 carfilzomib - Drug Profile 181 CBM-C19.1 - Drug Profile 185 CBM-C20.1 - Drug Profile 186 CC-122 - Drug Profile 188 CC-223 - Drug Profile 190 Cellular Immunotherapy for Oncology - Drug Profile 191 Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 192 cerdulatinib - Drug Profile 193 coltuximab ravtansine - Drug Profile 195 copanlisib hydrochloride - Drug Profile 197 CPI-0610 - Drug Profile 201 CPI-169 - Drug Profile 202 CUDC-907 - Drug Profile 203 CYC-065 - Drug Profile 205 daratumumab - Drug Profile 206 Darleukin - Drug Profile 210 denintuzumab mafodotin - Drug Profile 212 DPX-Survivac - Drug Profile 213 E-7449 - Drug Profile 217 entospletinib - Drug Profile 218 epacadostat - Drug Profile 219 everolimus - Drug Profile 221 GS-5829 - Drug Profile 227 GSK-2816126 - Drug Profile 228 HMPL-523 - Drug Profile 229 IBL-301 - Drug Profile 230 ibrutinib - Drug Profile 232 idelalisib - Drug Profile 239 IGN-002 - Drug Profile 242 imexon - Drug Profile 243 IMGN-529 - Drug Profile 245 IMO-8400 - Drug Profile 247 inebilizumab - Drug Profile 249 inebilizumab + rituximab - Drug Profile 251 inotuzumab ozogamicin - Drug Profile 252 IT-901 - Drug Profile 254 ixazomib citrate - Drug Profile 255 JCAR-014 - Drug Profile 259 JNJ-64052781 - Drug Profile 260 KA-2237 - Drug Profile 261 KTEC-19 - Drug Profile 262 lenalidomide - Drug Profile 265 mitoxantrone hydrochloride - Drug Profile 270 MK-2206 - Drug Profile 271 MK-8628 - Drug Profile 274 mocetinostat - Drug Profile 276 Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers - Drug Profile 279 Monoclonal Antibody to Agonize CD40 for Diffuse Large B-Cell Lymphoma and Solid Tumors - Drug Profile 280 MOR-208 - Drug Profile 281 MRX-34 - Drug Profile 283 NBD Peptide - Drug Profile 285 ND-2110 - Drug Profile 287 ND-2158 - Drug Profile 289 nivolumab - Drug Profile 291 NMIL-121 - Drug Profile 299 obinutuzumab - Drug Profile 301 ONC-201 - Drug Profile 304 pecazine - Drug Profile 307 pembrolizumab - Drug Profile 308 pidilizumab - Drug Profile 317 pixantrone dimaleate - Drug Profile 319 PNT-2258 - Drug Profile 323 polatuzumab vedotin - Drug Profile 325 PRT-060318 - Drug Profile 327 Pt-EC-G - Drug Profile 328 rituximab biosimilar - Drug Profile 329 rituximab biosimilar - Drug Profile 330 rituximab biosimilar - Drug Profile 331 rituximab biosimilar - Drug Profile 333 rituximab biosimilar - Drug Profile 334 romidepsin - Drug Profile 335 RP-6530 - Drug Profile 338 ruxolitinib phosphate - Drug Profile 339 SEL-24B489 - Drug Profile 344 selinexor - Drug Profile 345 SGN-CD70A - Drug Profile 351 SH-7129 - Drug Profile 352 Small Molecule to Inhibit IRAK-4 for Cancer and Inflammation - Drug Profile 354 Small Molecules for Diffuse Large B Cell Lymphoma - Drug Profile 355 Small Molecules to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile 356 Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 357 Small Molecules to Inhibit NF-kappa B for Diffuse Large B-Cell Lymphoma - Drug Profile 358 sotrastaurin acetate - Drug Profile 359 spebrutinib besylate - Drug Profile 361 Synthetic Peptide to Inhibit Bcl-6 for Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukemia - Drug Profile 363 Synthetic Peptides to Target RBCK1 for Diffuse Large B-cell Lymphoma - Drug Profile 364 TAK-659 - Drug Profile 365 TAS-5567 - Drug Profile 366 tazemetostat - Drug Profile 367 tisagenlecleucel-T - Drug Profile 369 ublituximab + TGR-1202 - Drug Profile 372 ulocuplumab - Drug Profile 373 urelumab - Drug Profile 375 valproate sodium - Drug Profile 377 venetoclax - Drug Profile 378 vorinostat - Drug Profile 382 yttrium Y 90 epratuzumab tetraxetan - Drug Profile 386 Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 387 Diffuse Large B-Cell Lymphoma - Dormant Projects 631 Diffuse Large B-Cell Lymphoma - Discontinued Products 634 Diffuse Large B-Cell Lymphoma - Product Development Milestones 636 Featured News & Press Releases 636 Appendix 647 Methodology 647 Coverage 647 Secondary Research 647 Primary Research 647 Expert Panel Validation 647 Contact Us 647 Disclaimer 648
List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2015 21 Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2015 22 Number of Products under Development by Companies, H2 2015 24 Number of Products under Development by Companies, H2 2015 (Contd..1) 25 Number of Products under Development by Companies, H2 2015 (Contd..2) 26 Number of Products under Development by Companies, H2 2015 (Contd..3) 27 Number of Products under Development by Companies, H2 2015 (Contd..4) 28 Number of Products under Development by Companies, H2 2015 (Contd..5) 29 Number of Products under Investigation by Universities/Institutes, H2 2015 30 Comparative Analysis by Late Stage Development, H2 2015 31 Comparative Analysis by Clinical Stage Development, H2 2015 32 Comparative Analysis by Early Stage Development, H2 2015 33 Products under Development by Companies, H2 2015 34 Products under Development by Companies, H2 2015 (Contd..1) 35 Products under Development by Companies, H2 2015 (Contd..2) 36 Products under Development by Companies, H2 2015 (Contd..3) 37 Products under Development by Companies, H2 2015 (Contd..4) 38 Products under Development by Companies, H2 2015 (Contd..5) 39 Products under Development by Companies, H2 2015 (Contd..6) 40 Products under Development by Companies, H2 2015 (Contd..7) 41 Products under Investigation by Universities/Institutes, H2 2015 42 Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H2 2015 43 Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 44 Diffuse Large B-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 45 Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H2 2015 46 Diffuse Large B-Cell Lymphoma - Pipeline by Aprogen, Inc., H2 2015 47 Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 48 Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015 49 Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H2 2015 50 Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2015 51 Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H2 2015 52 Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 53 Diffuse Large B-Cell Lymphoma - Pipeline by BIND Therapeutics, Inc., H2 2015 54 Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H2 2015 55 Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 56 Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H2 2015 57 Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2015 58 Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 59 Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 60 Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H2 2015 61 Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H2 2015 62 Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 63 Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015 64 Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2015 65 Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H2 2015 66 Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 67 Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H2 2015 68 Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 69 Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015 70 Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015 71 Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 72 Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015 73 Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 74 Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H2 2015 75 Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H2 2015 76 Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2015 77 Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015 78 Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2015 79 Diffuse Large B-Cell Lymphoma - Pipeline by Karus Therapeutics Limited, H2 2015 80 Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 81 Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015 82 Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H2 2015 83 Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H2 2015 84 Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015 85 Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H2 2015 86 Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 87 Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 88 Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015 89 Diffuse Large B-Cell Lymphoma - Pipeline by Mirna Therapeutics, Inc., H2 2015 90 Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H2 2015 91 Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H2 2015 92 Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2015 93 Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2015 94 Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015 95 Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H2 2015 96 Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 97 Diffuse Large B-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 98 Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H2 2015 99 Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H2 2015 100 Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 101 Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015 102 Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2015 103 Diffuse Large B-Cell Lymphoma - Pipeline by Redx Pharma Plc, H2 2015 104 Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H2 2015 105 Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2015 106 Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H2 2015 107 Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 108 Diffuse Large B-Cell Lymphoma - Pipeline by Selvita SA, H2 2015 109 Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015 110 Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 111 Assessment by Monotherapy Products, H2 2015 112 Assessment by Combination Products, H2 2015 113 Number of Products by Stage and Target, H2 2015 115 Number of Products by Stage and Mechanism of Action, H2 2015 120 Number of Products by Stage and Route of Administration, H2 2015 124 Number of Products by Stage and Molecule Type, H2 2015 126 Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 395 Diffuse Large B-Cell Lymphoma - Dormant Projects, H2 2015 639 Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H2 2015 640 Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H2 2015 641 Diffuse Large B-Cell Lymphoma - Discontinued Products, H2 2015 642 Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H2 2015 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
